Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Current Assets data on record, last reported at $528.1 million in Q4 2025.

  • For Q4 2025, Current Assets fell 12.43% year-over-year to $528.1 million; the TTM value through Dec 2025 reached $528.1 million, down 12.43%, while the annual FY2025 figure was $528.1 million, 12.43% down from the prior year.
  • Current Assets reached $528.1 million in Q4 2025 per SNDX's latest filing, roughly flat from $529.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $603.1 million in Q4 2024 and bottomed at $238.3 million in Q3 2021.
  • Average Current Assets over 5 years is $437.8 million, with a median of $443.8 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 167.69% in 2021, then fell 12.43% in 2025.
  • A 5-year view of Current Assets shows it stood at $448.4 million in 2021, then grew by 9.23% to $489.8 million in 2022, then rose by 18.6% to $580.9 million in 2023, then increased by 3.82% to $603.1 million in 2024, then dropped by 12.43% to $528.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $528.1 million in Q4 2025, $529.8 million in Q3 2025, and $531.7 million in Q2 2025.